Auriga Laboratories Enters Into Trade Development Agreement with New Pharmaceutical Strategies (NPS).

Agreement Expected to Accelerate Adoption of Company's Product Portfolio

NORCROSS, Ga. -- Auriga Laboratories, Inc. (OTCBB: ARGA) or "Auriga", a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and Xerostomia, announced today that it has entered into a trade development agreement, under which New Pharmaceutical Strategies (NPS, a division of VCG & Associates), will develop trade development strategies and initiatives focused on enhancing sales of Auriga's product line. Under the two-year agreement, NPS will focus on enhancing sales of Auriga's products by expanding its position in the retail and drug wholesale marketplace.

VCG & Associates (VCG) is an independent strategic marketing and contract services provider specializing in working with emerging pharmaceutical, biotech and technology companies providing strategies, tactics and resources related to commercial product launch activities. VCG & Associates fields one of the largest contract National Account teams in the industry providing manufacturers the access to key decision makers in order to help accelerate the selling process to the third party market. NPS provides consulting services and contract resources related to pharmaceutical product distribution and supply chain management.

"The co-promotion agreement with NPS represents an ideal trade and distribution strategy for Aquoral[TM] and other products in our portfolio," said Philip S. Pesin, Chief Executive Officer of Auriga. "NPS's experienced management team has excellent relationships with all classes of trade, giving Auriga significant opportunity to expand distribution of our Extendryl[R] and Levall[R] product lines. This, coupled with Auriga's active development pipeline and plan to launch 15 new products, gives us even greater confidence in our ability to execute and achieve the goals set forth in our business plan."

"We are excited by the current and future portfolio of products offered by Auriga and the opportunity to apply our combined experience in having assisted more than 50 pharmaceutical companies with their launch efforts," stated Dan Steiber, Partner, VCG & Associates responsible for Trade Development and Commercial Operations.

NPS will be responsible for all trade development, national accounts and supply chain initiatives on behalf of Auriga and in effect will function as the in-house trade team. Horace Cook (NPS), Ed Conroy (NPS) and Frank Lasusa (Auriga), three experienced pharmaceutical executives will lead the Auriga Trade Team. The group will report into Andrew Shales, Chief Operating Officer for Auriga.

About Auriga Laboratories[TM]

Auriga Laboratories[TM] is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive prescription product portfolio currently includes Aquoral[TM] for the treatment of Xerostomia, Akurza[TM] and Xyralid[TM] dermatology products, and the Extendryl[R] and Levall[R] families of products for relief of symptoms associated with a range of acute respiratory diseases. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com.

Forward-Looking Statements:

The information contained herein includes forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the Company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the Company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the Company's ability to secure additional financing, its ability to sustain market acceptance for its products, its dependence on collaborators, the Company's ability to find and execute strategic transactions, its potential exposure to litigation, the Company's exposure to product liability claims, and the Company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.